MaxCyte, Inc. Strategic Platform License with Prime Medicine (9132H)
August 01 2023 - 8:05AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 9132H
MaxCyte, Inc.
01 August 2023
MaxCyte Signs Strategic Platform License with Prime Medicine to
Advance Next-Generation Gene Editing Therapies for Patients
Prime Medicine to use MaxCyte's Flow Electroporation(R)
technology and ExPERT(TM) platform to advance their innovative
Prime Editing technology and develop a new class of one-time,
potentially curative therapies
ROCKVILLE, MD , August 1, 2023 - MaxCyte, Inc. , (Nasdaq: MXCT;
LSE: MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell-based
therapeutics and to support innovative, cell-based research, today
announced the signing of a strategic partnership with Prime
Medicine, Inc. , a biotechnology company committed to delivering a
new class of differentiated one-time curative genetic
therapies.
Under the terms of the agreement, Prime Medicine obtains
non-exclusive clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform. In return,
MaxCyte is entitled to receive annual license fees and
program-related revenue .
"We are pleased to partner with Prime Medicine and support their
breakthrough gene editing technology," said Doug Doerfler,
President and CEO of MaxCyte. "The company's innovative vision and
transformative scientific approach are clearly reshaping how
genetic diseases are studied and ultimately will be treated."
Prime Medicine is a leading biotechnology company dedicated to
creating and delivering the next generation of gene editing
therapies to patients. The Company is leveraging its proprietary
Prime Editing platform, a versatile, precise and efficient gene
editing technology, to develop a new class of differentiated,
one-time, potentially curative genetic therapies. Designed to make
only the right edit at the right position within a gene while
minimizing unwanted DNA modifications, Prime Editors have the
potential to repair almost all types of genetic mutations and work
in many different tissues, organs and cell types.
MaxCyte's ExPERT(TM) instrument portfolio is the next generation
of leading, clinically-validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability, and enhanced
functionality, the ExPERT(TM) platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Prime Medicine is MaxCyte's 23(rd) strategic
partnership overall, each of which generates pre-commercial
milestone revenue and the vast majority of which include
sales-based payments.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT (TM) family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn .
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGREANPFEFPDEEA
(END) Dow Jones Newswires
August 01, 2023 08:05 ET (12:05 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024